Image

Predictive Value of Vasodilator Challenge for Right Heart Failure After LVAD Implantation

Predictive Value of Vasodilator Challenge for Right Heart Failure After LVAD Implantation

Non Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Prospective evaluation of the predictive value for post-LVAD right ventricular failure (RHF) of pulmonary vasodilator challenge, in addition to current laboratory, echocardiographic and haemodynamic parameters.

LVAD candidates satisfying the inclusion criteria will undergo vasodilator challenge with sodium nitroprusside (NTP) infusion following the study protocol.

Thereafter, we will evaluate all data in order to determine which variables significantly correlate with RHF onset after LVAD implantation.

Description

Inclusion criteria

  • Age over 18 years old.
  • Diagnosis of advanced heart failure with an indication for LVAD implantation.
  • Mean Arterial Pressure (MAP) > 60 mmHg; Mean Pulmonary Arterial Pressure (mPAP) > 20 mmHg; Pulmonary Artery Wedge Pressure >15 mmHg.
  • Vasodilator Challenge performed through NTP infusion.

Exclusion criteria

  • State of pregnancy.
  • Inability to perform vasodilator challenge
  • Need for extracorporeal membrane oxygenator or short-term right ventricular assist devices.
  • Planned right ventricular assist device implantation in the peri-procedural setting.

Right heart catheterization (RHC) RHC will be performed under optimal medical therapy within 90 days before LVAD implantation.

Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drops below 85 mmHg.

Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.

All haemodynamic measurements will be repeated after nitroprusside infusion and titration.

Right heart failure (RHF) Post-operative RHF will be evaluated according to the definition proposed by the 2020 consensus statement of the mechanical circulatory support academic research consortium (1).

Eligibility

Inclusion criteria

  • Age over 18 years old.
  • Diagnosis of advanced heart failure with an indication for LVAD implantation.
  • Mean Arterial Pressure (MAP) > 60 mmHg; Mean Pulmonary Arterial Pressure (mPAP) > 20 mmHg; Pulmonary Artery Wedge Pressure >15 mmHg.
  • Vasodilator Challenge performed through NTP infusion.

Exclusion criteria

  • State of pregnancy.
  • Inability to perform vasodilator challenge
  • Need for extracorporeal membrane oxygenator or short-term right ventricular assist devices.
  • Planned right ventricular assist device implantation in the peri-procedural setting.

Study details
    Right Heart Failure

NCT05836233

San Camillo Hospital, Rome

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.